Cytokinetics, Incorporated (CYTK) Covered Calls
Cytokinetics, Incorporated (CYTK) is a commercial-stage biopharmaceutical leader focused on muscle biology. In 2026, the firm reached a turning point with the U.S. and European launch of MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy (oHCM). The company is now leveraging its $1.2B cash reserve to expand its cardiovascular portfolio into non-obstructive heart conditions and heart failure.
You can sell covered calls on Cytokinetics, Incorporated to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for CYTK (prices last updated Tue 4:16 PM ET):
| Cytokinetics, Incorporated (CYTK) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 65.80 | -0.34 | 65.32 | 66.18 | 911K | - | 8.1 |
| Covered Calls For Cytokinetics, Incorporated (CYTK) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| May 15 | 65 | 11.10 | 55.08 | 18.0% | 263% | |
| Jun 18 | 65 | 11.80 | 54.38 | 19.5% | 121% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Commercial Execution and aficamten Launch
Cytokinetics (NASDAQ: CYTK) successfully transitioned to a commercial entity in early 2026 following the FDA and EU approval of MYQORZO (aficamten). The drug, a next-generation cardiac myosin inhibitor, is being positioned as a "best-in-class" treatment for oHCM due to its predictable dosing and favorable safety profile. Initial Q1 2026 sales data indicates strong adoption among cardiologists, supported by a specialized U.S. sales force and a strategic expansion into the German and Chinese markets.
Competitive Landscape
CYTK competes directly with Bristol Myers Squibb (BMS) in the cardiac myosin inhibitor class. While BMS was first-to-market with Camzyos, Cytokinetics differentiates MYQORZO through simpler dose titration and lower monitoring burdens. Despite recurring acquisition rumors, CYTK remains independent as of April 2026, focused on capturing the multi-billion dollar obstructive and non-obstructive cardiomyopathy markets.
Publicly traded competitors that are optionable include:
- Bristol-Myers Squibb: The primary rival with the first-generation HCM drug Camzyos.
- Vertex Pharmaceuticals: A high-liquidity biotech peer focused on specialty medicine.
- Madrigal Pharmaceuticals: A peer undergoing a similar transition to commercial-stage cardiovascular sales.
2026 Outlook and Key Catalysts
The defining catalyst for the remainder of 2026 is the **Phase 3 ACACIA-HCM data readout** expected in Q2, which evaluates aficamten for non-obstructive HCM. Success here would roughly double the drug's addressable market. Investors are also monitoring the May 2026 earnings call for the first full quarter of U.S. commercial revenue, which will set the benchmark for the company’s valuation through year-end.
| Top 10 Open Interest For May 15 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | SLV covered calls | 6. | SPY covered calls | 1. | CAR covered calls | |
| 2. | NVDA covered calls | 7. | HYG covered calls | 2. | USO covered calls | |
| 3. | IBIT covered calls | 8. | QQQ covered calls | 3. | CMPX covered calls | |
| 4. | GLD covered calls | 9. | KWEB covered calls | 4. | QS covered calls | |
| 5. | TLT covered calls | 10. | EEM covered calls | 5. | NOW covered calls | |
Want more examples? CYRX Covered Calls | CZNC Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
